期刊文献+

2型糖尿病患者糖尿病视网膜病变的预测性因素研究 被引量:9

Predictive factors of type 2 diabetic retinopathy
下载PDF
导出
摘要 目的探讨2型糖尿病患者糖尿病视网膜病变(diabetic retinopathy,DR)的预测性因素。方法 628例2型糖尿病患者纳入本研究,记录糖尿病危险因素、并发症及实验室检查结果。运用SPSS 16.0软件包建立数据库,并用χ2检验进行统计学分析,Logistic回归分析危险因素和DR的关系。结果 628例2型糖尿病患者(46%为男性)中DR患者166例(占26.4%)。DR和糖尿病家族史(P=0.040 0)、高血压(P=0.000 1)、糖尿病病程(P=0.000 1)、血糖控制不良(P=0.000 1)及糖尿病发病年龄(P=0.000 1)均有显著关联。然而DR和血脂及肥胖并未发现有相关性(均为P>0.05)。Logistic回归分析中,对年龄及性别进行调整以后,血糖控制不佳(P=0.014)、高血压(P=0.000 1)、糖尿病病程(P=0.000 1)和糖尿病家族史(P=0.012)均是DR的独立危险因素。结论基因及环境等后天性因素对DR的发生发展会产生影响。 Objective To assess the predictive factors of type 2 diabetic retinop- athy (DR). Methods A cross-sectional study was designed by recruiting 528 type 2 diabetic patients. Diabetes risk factors, complications, laboratory results were recorded. SPSS 15.0 software was used to establish the database, and the relationship between predictive factors and DR was analyzed by Logistic regression analysis. Results Of the 528 diabetic patients (45% man) ,prevalence of DR was 25.4%. There were significant associations between DR and family history of diabetes (P = 0.040 0), hyperten- sion (P = 0. 000 1 ), diabetic duration ( P = 0. 000 1 ), poor glycemic control ( P = 0. 000 1 ) and age of onset of diabetes (P = 0. 000 1 ). However, no significant associa- tions were found between DR and dyslipidemia, obesity ( all P 〉 0.05 ). In Logistic regression model,poor glycemic control (P = 0. 014 0) ,hypertension (P = 0. 000 1 ), duration of diabetes (P =0.000 1 ) and family history of diabetes (P =0.012 0) independently predicted DR after adjustment for age and sex. Conclusion The genetic and epigenetic factors are the predictive factors for DR.
作者 袁媛
出处 《眼科新进展》 CAS 北大核心 2015年第8期784-786,共3页 Recent Advances in Ophthalmology
关键词 糖尿病视网膜病变 预测性因素 糖尿病家族史 diabetic retinopathy predictive factor family history of diabetes
  • 相关文献

参考文献20

  • 1Ceriello A, Ihnat MA, Thorpe JE. The "Metabolic Memory" :is more than just tight glucose control necessary to prevent diabet- ic complications [ J ] ? J Clin Endocrinol Metab , 2009, 13 ( 4 ) : 410-415.
  • 2Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Or- chard T J, et al. Clinical factors associated with resistance to mi- crovascular complications in diabetic patients of extreme dis- ease duration : tile 50-year medalist study[J].Diabetes Care, 2007,13 ( 8 ) : 1995-1997.
  • 3Fong DS, Aiello LP, FerNs FL, Klein R. Diabetic retinopathy [ J ]. Diabetes Care ,2004,13 ( 20 ) :2540-2553.
  • 4Harris MI, Klein R, Welbom TA, Knutmml MW. Onset of NIDDM occurs at least 4-7 year before clinical diagnosis [ J ]. Diabetes Care,1992,13(8) :815-819.
  • 5Williams WW, Salem RM, McKnight A J, Sandholm N, Forsblom C ,Taylor A,et al. Association testing of previously reported va- riants in a large case-control meta-analysis of diabetic nephrop- athy[ J]. Diabetes ,2012,13 ( 8 ) :2187-2194.
  • 6Looker HC, Nelson RG, Chew E, Klein BE, Knowler WC, Hanson RL, et al. Genome-wide linkage analyses to identify loci for dia- betic retinopathy [ J ]. Diabetes,2007,13 (4) : 1160-1166.
  • 7Hallman DM, Boerwinkle E, Gonzale VII, Klein BE, Klein R, Ha- nis CL. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County,Texas[J]. Diabetes,2007,13(4) :1167-1173.
  • 8Torres JM, Cox N J, Philipson LH. Genome wide association studies for diabetes:perspective on results and challenges [ J ]. Pediatr Diabetes ,2013,13 ( 1 ) :90-96.
  • 9Donaghue KC,Margan SH, Chan AK,Holloway B, Silink M, Ran- gel T,et al. The association of aldose reductase gene( AKR1 B1 ) polymorphisms with diabetic neuropathy in adolescents[ J]. Dabet Meal,2005,13 (8) : 1315-1320.
  • 10Ma J, Li Y, Zhou F, Xu X, Guo G, Qu Y. Meta-analysis of associa- tion between the Prol2Ala polymorphism of the peroxisome proliferator-activated receptor-@ gene and diabetic retinopathy in Caucasians and Asians[ J]. Mol Vis,2012,13(20) :2352-2360.

二级参考文献8

  • 1Gunes F,Akbal E,Cakir E,et al.Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients[J].Intern Med,2012,51(6):553-557.
  • 2Pan H Y,Guo L,Li Q.Changes of serum omentin-l levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes[J].Diabetes Res Clin Pract,2010,88(1):29-33.
  • 3Moreno-Navarrete J M,Ortega F,Castro A,et al.Circulating omentin as a novel biomarker of endothelial dysfunction[J].Obesity(Silver Spring),2011,19(8):1552-1559.
  • 4Yamawaki H,Tsubaki N,Mukohda M,et al.Omentin,a novel adipokine,induces vasodilation in rat isolated blood vessels[J].Biochem Biophys Res Commun,2010,393(4):668-672.
  • 5Na Z,James S,Pankow C M,et al.High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study[J].J Clin Endocrinol Metab,2010,95(11):5097-5104.
  • 6Woo Y C,Tso A W,Xu A.et al.Combined use of serum adiponectin and tumor necrosis factor-alpha receptor 2 levels was comparable to 2-hour post-load glucose in diabetes prediction[J].PLo S One,2012,7(5):e36868.
  • 7Brown J E,Onyango D J,Ramanjaneya M,et al.Visfatin regulates insulin secretion,insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells[J].J Mol Endocrinol,2010,44(3):171-178.
  • 8Schutte A E,Huisman H W,Schutte R.et al.Adipokines and cardiometabolic function:how are they interlinked[J].Regul Pept,2010,164(2/3):133-138.

共引文献7

同被引文献119

引证文献9

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部